DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for acrokeratosis verruciformis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAcrokeratosis verruciformis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for acrokeratosis verruciformis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 (ATP2A2) — ATP2A2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet befdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6LLY · 2.8 Å · ligand BERYLLIUM TRIFLUORIDE ION (BEF). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Dermatology · 2010 · 27 citations
A sporadic patient with acrokeratosis verruciformis of Hopf and a novel <i>ATP2A2</i> mutation
AbstractConflicts of interest: none declared. Madam, Acrokeratosis verruciformis (AKV) is a rare autosomal dominant or sporadic genodermatosis. Affected individuals demonstrate asymptomatic, flat‐topped, skin‐coloured papules on the dorsal hands and feet. On histological examination, AKV demonstrates marked compact orthokeratosis, hypergranulosis, mild regular acanthosis and variable ‘church spire’ papillomatosis, without viral cytopathic changes, parakeratosis, acantholysis or dyskeratosis. It has long been hypothesized that AKV is allelic to Darier disease. However, the literature contains just two reports of genetic analyses of patients with AKV,1, 2 only one of which documented mutations in ATP2A2, which is the gene defect in Darier disease.1 That report included one family with a novel P602L mutation in ATP2A2. Here, we present the second report of ATP2A2 mutations in AKV, in this case resulting in an A698V codon change which has never been described in patients with either AKV or Darier disease. An 11‐year‐old Afghani boy presented with a 6‐year history of asymptomatic bumps on the hands and feet. He had been diagnosed with verruca plana and treated with cryotherapy, cimetidine and topical tretinoin, imiquimod and salicylic acid, none of which resulted in significant improvement. Past medical history was unremarkable. There was no family history of similar lesions, Darier disease or consanguinity. Physical examination revealed 1–4‐mm verrucous, flat‐topped papules over the dorsal hands, wrists, feet and ankles (Fig. 1). The remaining physical examination was normal, including palms and nails. A shave biopsy from the hand taken 4 years earlier at an another institution, and a repeat shave biopsy (Fig. 2) from the hand both demonstrated marked hyperkeratosis overlying a slightly acanthotic epidermis with hypergranulosis and ‘church spire’ papillomatosis. Parakeratosis, cytoplasmic vacuolization suggestive of viral cytopathic change, acantholysis and dyskeratosis were absent. Based on the clinical–pathological correlation, a diagnosis of AKV was made.
Journal of Dermatological Treatment · 2007 · 23 citations
Acitretin treatment in acrokeratosis verruciformis of Hopf
AbstractAcrokeratosis verruciformis of Hopf is a rare disorder and characterized by flesh-coloured, wart-like, flat papules on the dorsum of the hands and feet. The disease is an autosomal disorder, but sporadic cases also occur. We present a 38-year-old woman diagnosed with acrokeratosis verruciformis without family history and treated successfully with acitretin.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
